News

Tau bio-logic and LifeArc researchers have generated a human-like antibody called TBL-100 for the treatment of Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). An antibody is a large Y-shaped protein that’s naturally produced in response to invading foreign particles (antigens) such as viruses. A humanized…

A cellular model that simulates the blood-brain barrier — a membrane that protects against viruses or other insults entering through the blood stream — may help in understanding how potential treatments for neurological diseases like Alzheimer’s could better cross that barrier to reach the brain and central nervous system, its creators…

Cognitive training alone — without the use of direct brain stimulation — may significantly benefit adults with mild cognitive impairment, a known risk factor for Alzheimer’s disease, a pilot clinical study reports. The study, “Cognitive Training and Transcranial Direct Current Stimulation in Mild Cognitive Impairment: A Randomized Pilot Trial,”…

Treatment with naproxen, an anti-inflammatory medication, failed to prevent the progression of Alzheimer’s in individuals at risk of developing the disease, results from a Phase 2 clinical trial show. The results, “INTREPAD: A randomized trial of naproxen to slow progress of…

While caregiving for people with Alzheimer’s and other disorders has a significant detrimental impact on caregivers’ immune system, the association is weak — less than 1% — and may not carry clinical significance, a new study shows. “We’re not saying that family caregiving can’t be stressful, but there’s a notion…

To enable researchers to study prospective links between sleep and dementia, a cutting-edge sleep unit has opened at the University of East Anglia (UEA) in Norwich, England. While sleeping issues commonly occur in dementia, it’s unclear whether diseases such as Alzheimer’s cause the disturbances, or whether problems sleeping signal…

A Phase 1 trial evaluating Samumed’s investigational compound SM07883 for Alzheimer’s disease has dosed its first participant. The Phase 1 trial (ACTRN12619000327189), taking place in Australia, will assess the safety, tolerability, and pharmacokinetics (the movement of a medicine into, through, and out of the body) of ascending doses…

The investigational therapy azeliragon decreased inflammation and lessened cognitive decline and dementia in patients with mild Alzheimer’s disease and type 2 diabetes, compared with a placebo, according to data from a subgroup analysis of the Phase 3 STEADFAST study. The findings were described in the presentation, “Inflammatory Biomarkers, Brain…

Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the accumulation of amyloid plaques in patients with Alzheimer’s disease with and without amyloid-related imaging abnormalities-edema (ARIA-E).

Two prescription treatments for heart disease and angina — cilostazol and isosorbide mononitrate — show a potential to prevent or reduce vascular dementia, a study reports. They also can be safely used in people with a history of stroke, which was the focus of this research. Because vascular dementia and…